Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.38 |
| ▸ | CHRNG | P07510 | 1/20 | 0.38 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CHRND | Q07001 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26257358 | 1.00 | CTSL (0.42) | CTSLCYP2B6KDM4ESLC6A2CYP2C19 | |
| SCHEMBL25399092 | 1.00 | CTSL (0.42) | CTSLCYP2B6KDM4ESLC6A2CYP2C19 | |
| SCHEMBL29949243 | 0.87 | CTSL (0.41) | CTSLKDM4ESLC6A2CYP2C19CHRNA1 | |
| SCHEMBL24944766 | 0.85 | CTSL (0.42) | CTSLCYP2B6KDM4ECYP2C19MAPT | |
| SCHEMBL19731493 | 0.85 | CTSL (0.42) | CTSLCYP2B6KDM4ECYP2C19MAPT | |
| SCHEMBL4595970 | 0.84 | CTSL (0.41) | CTSLCYP2B6KDM4ECYP2C19MAPT | |
| SCHEMBL244890 | 0.84 | AAK1 (0.45) | SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL15124774 | 0.84 | AAK1 (0.45) | SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL19265256 | 0.84 | RXFP1 (0.48) | KDM4ECYP2C19MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL10216897 | 0.84 | RXFP1 (0.48) | KDM4ECYP2C19MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4493546-B1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2026-05-06 | — | — | EP | disclosed |
| EP-4493546-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2025-01-22 | — | — | EP | disclosed |
| US-12030856-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2024-07-09 | — | — | US | disclosed |
| US-11945811-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2024-04-02 | — | — | US | disclosed |
| EP-4313973-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2024-02-07 | — | — | EP | disclosed |
| US-20230406845-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-12-21 | — | — | US | disclosed |
| US-20230399301-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-12-14 | — | — | US | disclosed |
| WO-2023174836-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-09-21 | — | — | WO | disclosed |
| EP-4245753-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2023-09-20 | — | — | EP | disclosed |
| WO-2022200162-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACECION PHARMA APS (DK) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030856-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | CTSL 3805/4885CYP2B6 2363/4885KDM4E 1829/4885 |
| US-11945811-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | CTSL 3805/4885CYP2B6 2363/4885KDM4E 1829/4885 |
| US-20230406845-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | CTSL 3759/4885CYP2B6 2693/4885KDM4E 1291/4885 |
| US-20230399301-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | CTSL 3759/4885CYP2B6 2693/4885KDM4E 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.